Sickle cell disease and beta thalassemia are the startup’s lead indications. While gene therapies are available for both blood disorders, Marrow executives say manufacturing and dosing advantages could make their medicine more broadly accessible across the world.
The post Marrow Therapeutics Unveils $173M for ‘Trojan Horse’ Delivery of Blood Disorder Drugs appeared first on MedCity News.